eFFECTOR Therapeutics, Inc. Warrant
EFTRW
EFTRW was delisted on the 2nd of July, 2024.
21 hedge funds and large institutions have $5.66M invested in eFFECTOR Therapeutics, Inc. Warrant in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 29 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
8% more capital invested
Capital invested by funds: $5.23M → $5.66M (+$427K)
45% less funds holding
Funds holding: 38 → 21 (-17)
59% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$1.78M |
| 2 |
Goldman Sachs
New York
|
+$616K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$182K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$68.4K |
| 5 |
AGM
Alpine Global Management
New York
|
+$49.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$1.27M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$1.08M |
| 3 |
LA
Linden Advisors
New York
|
-$316K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$201K |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$200K |
EFTRW Hedge Fund Activity: Q3 2021 in Review
21 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Warrant (EFTRW) for Q3 2021, worth a combined $5.66M — up 8.2% from $5.23M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of EFTRW and 12 opened new positions — a net loss of 17 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Aristeia Capital, adding an estimated $1.78M. The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $1.27M sold.
- 21 institutional investors held eFFECTOR Therapeutics, Inc. Warrant (EFTRW) as of Q3 2021, down from 38 in Q2 2021.
- Funds reported $5.66M of eFFECTOR Therapeutics, Inc. Warrant stock for Q3 2021, up 8.2% quarter-over-quarter.
- 12 funds opened new eFFECTOR Therapeutics, Inc. Warrant positions in Q3 2021 and 29 closed out, a net change of -17 holders.
- The largest eFFECTOR Therapeutics, Inc. Warrant buyer in Q3 2021 was Aristeia Capital, an estimated $1.78M added.
- The largest eFFECTOR Therapeutics, Inc. Warrant seller in Q3 2021 was Radcliffe Capital Management, an estimated $1.27M sold.
Based on aggregated 13F filings for Q3 2021.